

Original Research

An update in improving erectile dysfunction therapy in Indonesia by using Li-ESWT and tadalafil combination — vascular endothelial growth factor and peak systolic velocity comparison: a randomized clinical trial

Androniko Setiawan¹, Andrian Japari^{1,*}, Rosy Nur Febriani¹, Silvia Werdhy Lestari², Tjahjo Djojo Tanojo³, Maria Paulina Budyandini Dyah Pramesti⁴, Agustinus Agustinus⁴, Mu-hammad Hidayat Surya Atmaja⁵, Munawaroh Fitriah⁶, Budi Utomo⁷

¹Andrology Specialist Program, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Academic Hospital, 60286 Surabaya, Indonesia

²Department of Medical Biology, Faculty of Medicine, Universitas Indonesia, 16424 Jakarta, Indonesia

³Andrology Clinic, Dr. Soetomo General Academic Hospital, 60286 Surabaya, Indonesia

⁴Department of Medical Biology, Faculty of Medicine, Universitas Airlangga, 60115 Surabaya, Indonesia

⁵Radiology Unit, Dr. Soetomo General Academic Hospital, 60286 Surabaya, Indonesia

⁶Clinical Pathology Lab, Dr. Soetomo General Academic Hospital, 60286 Surabaya, Indonesia

⁷Department of Public Health, Faculty of Medicine, Universitas Airlangga, 60115 Surabaya, Indonesia

*Correspondence: andrian-2017@fk.unair.ac.id (Andrian Japari)

Submitted: 9 November 2021 Accepted: 8 December 2021 Published: 19 May 2022

Abstract

Background: Erectile dysfunction (ED) affects men's life desperately and the incidence increases continuously. There are a few lines of ED therapy, but there are still many ED cases that have not treated utterly. Therefore, research is needed to obtain the most appropriate line of ED therapy, based on the underlying mechanism of ED. The aim of this study is to analyze the effect of oral daily 2.5 mg of tadalafil administration and twice weekly Low Intensity Extracorporeal Shockwave Therapy (Li-ESWT) for 4 weeks in erectile dysfunction patients, based on Peak Systolic Velocity (PSV) and Vascular Endothelial Growth Factor (VEGF). **Methods:** A 26-sample clinical trial was conducted with pre and post-test control group design. Random allocation was done to divide the samples into two groups. Control group was given 2.5 mg oral daily tadalafil, while the experimental group, additional twice weekly Li-ESWT was given. Therapies were given for 4 weeks. All subjects were assessed using Erection Hardness Score (EHS) score, International Index of Erectile Function (IIEF-5) score, and Color Doppler Ultrasonography (CDUS) penis for PSV, and plasma level of VEGF twice, prior to and after therapy. **Results:** The experimental group showed significant improvement compared to the control group in EHS (delta) 2 (1–2) vs 1 (0–2); IIEF-5 (delta) 7 (3–15) vs 4 (0–11); PSV (delta) 2.60 ± 1.34 vs 1.28 ± 1.86 ; and VEGF (delta) 26.69 ± 24.23 vs 6.32 ± 25.43 . **Conclusions:** Li-ESWT and tadalafil combination therapy improved erectile dysfunction, specifically based on PSV and VEGF parameters.

Keywords: Erectile dysfunction; Li-ESWT; Tadalafil; PSV; VEGF

1. Introduction

Erectile dysfunction (ED) is defined as the inability to achieve and maintain penile erection sufficient for satisfactory sexual performance that last for at least three months [1,2]. ED incidence is increasing nowadays, especially in the older population. ED has a great impact in men's life [3]. Generally, ED can be classified into two major groups, which are psychogenic and organic ED [4]. The majority of the cases are organic ED. And, to be specific, the origin of these cases was due to the arterial vasculogenic problem [4]. In arterial vasculogenic ED, the main culprit is thought to be the endothelial dysfunction, which is nowadays commonly caused by metabolic disorders, such as diabetes, hypertension, and metabolic syndrome [2,5–8]. Other causes of organic ED are neurogenic problems, medications side effects, and endocrine disorders.

There are various therapeutic options that can be cho-

sen to improve ED. As the first-line therapies there are Phosphodiesterase type 5 (PDE-5) inhibitors and vacuum devices. While for the second line therapy is intracavernosal injection, and for the third line therapies are penile surgery and prosthesis [9,10]. In Indonesia, the available therapeutic strategy is merely by using oral PDE-5 inhibitors. Other treatment strategies cannot be implemented due to the unavailability of the drug and other modalities. A new modality, Low Intensity Extracorporeal Shockwave Therapy (Li-ESWT), which had been used overseas for erectile dysfunction was brought forward as a new hope for ED treatment in Indonesia [11–23]. Li-ESWT is considered as a restorative therapy which could modify the ability of the penile vasculature in order to achieve a better erection [22,24,25]. The mechanism behind the Li-ESWT was still in debate, but in previous animal studies, it was found that Li-ESWT could induce the increase of Vascular Endothe-



Table 1. Subjects characteristics.

Characteristics	Control group	Experimental group	Total	<i>p</i>
	n = 12	n = 14	n = 26	
Mean age (years old)	47.8	49.2	48.6	0.419
Mean spouses' age (years old)	44.7	45.9	45.3	0.620
Mean duration of ED (years)	1.7	3.4	2.6	0.147
Mean of waist circumference (cm)	91.4	97.9	94.9	0.118
Mean BMI (kg/m ²)	25.7	27.5	26.7	0.277
Comorbidities	Diabetes mellitus	25%	42.9%	34.6%
	Hypertension	33.3%	42.9%	38.5%
	Cardiac problems	16.7%	21.4%	19.2%
	Dyslipidemia	25%	50%	38.5%
	Hypogonadism	0%	35.7%	19.2%
	History of smoking	41.7%	28.6%	34.6%
	History of alcoholism	8.3%	7.1%	7.7%
	Other	50%	57.1%	53.8%
ED severities	Mild	58.3%	35.7%	46.2%
	Mild-Moderate	16.7%	35.7%	26.9%
	Moderate	25%	28.6%	26.9%
Median of EHS	2 (1–3)	2 (1–3)	2 (1–3)	0.573
Median of IIEF-5	16.5 (9–21)	15.5 (10–20)	16 (9–21)	0.716

Note: n, number of samples; ED, erectile dysfunction; BMI, body mass index; EHS, Erection Hardness Score; IIEF, International index of erectile function.

Comparison of IIEF-5, EHS, and mean duration of ED were done using Mann-Whitney test, as for other parameters, Independent *t*-test were used.

lial Growth Factor (VEGF), which can lead to angiogenesis [20,21,24,26–32]. Preliminary studies in human also resulting the same result [33]. Angiogenesis or neovascularization could be observed by using Peak Systolic Velocity (PSV) parameter by using Color Doppler Ultrasonography (CDUS). Few studies tried to assess PSV in flaccid state with various results, but it seemed that the result can be a predictive value [34–37].

In order to improve the treatment of erectile dysfunction in Indonesia, especially in Surabaya, East Java, we conducted an experimental study on the combined treatment of Li-ESWT and tadalafil at Soetomo Doctor Hospital in Surabaya. This study is the first study to use Li-ESWT to improve erectile dysfunction by examining VEGF and PSV parameters.

2. Materials and methods

2.1 Study setting

This randomized controlled, prospective clinical trial aims to evaluate the improvement of patients with erectile dysfunction treated with the combination of Li-ESWT and tadalafil based on VEGF and PSV parameters. The experiment took place in Andrology Clinic, Dr. Soetomo Hospital, Indonesia, between December 2019 and June 2020.

2.2 Subjects

Thirty men with age ranged from 40 to 55 years old, with ED history for at least 3 months, from our center (Andrology Clinic of Dr. Soetomo Hospital) were recruited in this study. The inclusion criteria were patients with mild, mild-moderate, and moderate ED, married and living with their spouses. While the exclusion criteria were psychogenic ED, physical trauma on genital area, spinal cord injury, malignancy, PDE-5 inhibitors contraindications, prior use of PDE-5 inhibitors, and anti-VEGF medication use (one month), and other conditions which render difficulties in implementing the Li-ESWT procedure.

2.3 Study protocols

A thorough clinical examination according to the study protocols, which consist of history taking, physical examination, CDUS for PSV and plasma VEGF level examinations were performed by all subjects prior the study. All subjects were given 2.5 mg daily oral tadalafil for 4 weeks as the first line therapy for ED according to the clinical guideline of our clinic. The Li-ESWT procedures were performed twice weekly for 4 weeks along with the 2.5 mg daily oral tadalafil therapy for the subjects in the experimental group. Placebo was not used in this study due to ethical considerations. At the end of therapy, the same examinations were done to all subjects thoroughly in order to get the post experiment results.

Table 2. Comparison of IIEF-5 scores.

Subject	IIEF-5 score		Pre-test–post-test comparison	
	Pre-test	Post-test	Delta	<i>p</i>
Control group (n = 12)	16.5 (9–21)	21 (9–25)	4 (0–12)	0.004*
Experimental group (n = 14)	15.5 (10–20)	23.5 (14–25)	7 (3–15)	0.001*
Total (n = 26)	16 (9–21)	22 (9–25)	5.5 (0–15)	

Note: IIEF, International index of erectile function; n, number of sample; *, sign of significance ($p < 0.05$).

Comparison of pre- and post-test IIEF-5 parameter was done using Wilcoxon's test.

2.4 Examination procedure

Erectile dysfunction was evaluated by Erection Hardness Score (EHS) and International Index of Erectile Function (IIEF) scores. EHS scores were obtained directly by asking the subjects after a brief explanation, while IIEF-5 scores were gained from the IIEF questionnaires which were filled by all subjects. Physical examinations were performed by the attending doctors in the Andrology Clinic which were not involved in this study. CDUS for PSV examinations were performed in the Radiology Unit of Dr. Soetomo Hospital by using GE Logiq 9 (GE Healthcare, Chicago, IL, USA). The plasma VEGF levels were measured using Raybiotech® Human VEGF-A ELISA kit (RayBiotech, Peachtree Corners, GA, USA), and the assays were done in the Clinical Pathology Laboratory of Dr. Soetomo Hospital.

2.5 Li-ESWT procedure

Li-ESWT procedures were performed by using BTL-6000 SWT Topline machine (BTL Industries, London, UK), with a 15 mm radial probe. Commercially made water-based gel was applied to the penis before Li-ESWT procedures. There were numerous earlier studies regarding the protocols of Li-ESWT for ED. In this study, Li-ESWT was delivered to five locations on the penis, which were distal, medial, and proximal portion of the penile shaft, and to the left and right crux of the penis. Energy density was set at 0.09 mJ/mm², frequency was set at 5 Hz, with a total of 300 shocks at each treatment point.

2.6 Tadalafil administration

Tadalafil (Cialis, Eli Lilly, UK) was administered 2.5 mg oral daily.

2.7 Statistical analysis

The statistical analysis was done by using Easy R (EZR) statistical software version 1.54 (Jichi Medical University, Saitama Medical Center, Saitama, Japan) [38]. The data are expressed in mean ± SD or median and range. Comparisons were done using paired *t* test or Wilcoxon

signed-rank test as appropriate for the between group pre- and post-test comparisons. As for the comparison between the experiment group and the control group, the independent *t* test or Mann-Whitney test is used as appropriate. Significance was set at 5% ($p < 0.05$).

3. Results

The baseline assessment prior to the study that shown in Table 1 were similar. There was no significant difference between the control and the experimental group ($p > 0.05$). Before starting the study, both groups showed similar baseline conditions. Three men in the control group and one man in the experimental group withdrew from the study due to personal problems.

At the end of the treatment, there were changes in IIEF-5 questionnaire scores and EHS scores in both groups. In Tables 2,3, the IIEF-5 questionnaire score in the control group increased 4.5 points ($p = 0.004$) and 1 point for EHS score ($p = 0.004$), while in the experimental group, the score increased 8 points for IIEF-5 questionnaire score ($p = 0.001$) and 2 points increase for the EHS score, ($p = 0.001$). In Table 4, there were no significant changes of VEGF level in control group although VEGF level increased 6.32 points ($p = 0.408$); however there were significant changes of the VEGF level in the experimental group with 26.7 points increase ($p = 0.001$). In Table 5, the PSV parameters of the two groups have significant changes, and the control group increased by 1.28 points ($p = 0.04$) and 2.60 points increase in experimental group ($p = 0.001$).

In Table 6, we compared the changes in the control with the experimental group to determine the efficacy of the therapy. Although the post-test result didn't seem to differ significantly, but after calculating the changes of the respective parameters (delta), we can see that between two groups there are significant statistical differences. The changes of IIEF-5 questionnaire score and EHS score in the experimental group showed more superior result than control group ($p = 0.047$ and $p = 0.032$ respectively). Experimental group had a better improvement in penile vascularization which was shown from the PSV parameter signifi-

Table 3. Comparison of EHS scores.

Subject	EHS core			Pre-test–post-test comparison
	Pre-test	Post-test	Delta	<i>p</i>
Control group (n = 12)	2 (1–3)	3 (1–4)	1 (0–2)	0.004*
Experimental group (n = 14)	2 (1–3)	4 (3–4)	2 (1–2)	0.001*
Total (n = 26)	2 (1–3)	3.5 (1–4)	1 (0–2)	

Note: EHS, Erection Hardness Score; n, number of sample; *, sign of significance ($p < 0.05$). Comparison of pre- and post-test EHS parameter was done using Wilcoxon’s test.

Table 4. Comparison of VEGF values.

Subject	VEGF level (pg/mL)			Pre-test–post-test comparison
	Pre-test	Post-test	Delta	<i>p</i>
Control group (n = 12)	59.92 ± 41.91	66.24 ± 49.42	6.32 ± 25.43	0.408
Experimental group (n = 14)	57.95 ± 25.92	84.65 ± 40.71	26.69 ± 24.23	0.001*
Total (n = 26)	58.86 ± 33.52	76.15 ± 44.99	17.29 ± 26.40	

Note: VEGF, Vascular Endothelial Growth Factor; n, number of sample; *, sign of significance ($p < 0.05$).

Comparison of pre- and post-test VEGF parameter was done using paired *t*-test.

Table 5. Comparison of PSV values.

Subject	PSV (cm/s)			Pre-test–post-test comparison
	Pre-test	Post-test	Delta	<i>p</i>
Control group (n = 12)	11.40 ± 3.47	12.68 ± 3.90	1.28 ± 1.86	0.04*
Experimental group (n = 14)	11.14 ± 1.79	13.74 ± 2.10	2.60 ± 1.34	0.001*
Total (n = 26)	11.26 ± 2.64	13.25 ± 3.04	1.99 ± 1.70	

Note: PSV, Peak Systolic Velocity; n, number of sample; *, sign of significance ($p < 0.05$).

Comparison of pre- and post-test PSV parameter was done using paired *t*-test.

cant changes compared to control group ($p = 0.009$). The VEGF level also showed better improvement in experimental group compared to control group, and it was statistically significant ($p = 0.023$). The increase of all parameter in the experimental group are higher than in the control group, which mean that the addition of Li-ESWT to the standard therapy provided more outstanding result.

Furthermore, Fig. 1 showed a positive correlation (by using Spearman correlation test) between changes in the IIEF-5 questionnaire score and changes in the PSV parameter significantly ($p = 0.048$).


**Fig. 1. Correlation of delta PSV and IIEF-5.**

Table 6. Comparison of all parameters between groups.

Parameter	Control group	Experimental group	<i>p</i>	
IIEF-5	Pre-test	16.5 (9–21)	15.5 (10–20)	0.716
	Post-test	21 (9–25)	23.5 (14–25)	0.047*
	Delta	4 (0–11)	7 (3–15)	0.047*
EHS	Pre-test	2 (1–3)	2 (1–3)	0.573
	Post-test	3 (1–4)	4 (3–4)	0.018*
	Delta	1 (0–2)	2 (1–2)	0.032*
VEGF	Pre-test	59.92 ± 41.91	57.95 ± 25.92	0.885
	Post-test	66.24 ± 49.42	84.65 ± 40.71	0.308
	Delta	6.32 ± 25.43	26.69 ± 24.23	0.023*
PSV	Pre-test	11.40 ± 3.47	11.14 ± 1.79	0.813
	Post-test	12.68 ± 3.90	13.74 ± 2.10	0.385
	Delta	1.28 ± 1.86	2.60 ± 1.34	0.009*

Note: IIEF, International index of erectile function; EHS, Erection Hardness Score; PSV, Peak Systolic Velocity; VEGF, Vascular Endothelial Growth Factor; *, statistically significant ($p < 0.05$).

Comparison between groups for pre-test and post-test VEGF parameters were done using Independent *t*-test, as for the others parameters, the statistics methods used was Mann-Whitney test.

4. Discussion

The prevalence of erectile dysfunction remains high up until now, especially the organic ED that caused by arterial vasculogenic problems, and the PDE-5 inhibitors are still the main choice of therapy for this kind of ED [1,39]. But, the underlying cause behind the occurrence of arterial vasculogenic ED, which is believed to be the endothelial dysfunction, is still remain untouched. The therapy should be focused toward the endothelial dysfunction, which up until now, is still not solved by PDE-5 inhibitors as the first line therapeutic option. Newer therapies have been invented to improve ED, but almost none of them are focused on repairing the endothelial function. Regenerative therapies, such as stem cells, theoretically are able to repair these underlying mechanisms, but still no astonishing result was seen. Shock wave, especially low intensity shock wave, which is delivered from extra corporeal, seems to have a capability to induce regenerative process to repair the endothelial function. Prior studies have shown promising results.

In this study, we want to dwell further into Li-ESWT effects, clinically, as well as biochemically and radiologically, by assessing changes on IIEF-5 questionnaire score and EHS score, and evaluating the vascular regeneration process of the penile based on PSV parameter, and VEGF level as an angiogenesis factor.

In ED, CDUS is used to monitor the blood flow in cavernous arteries to confirm the penile vasculature [35,40–43]. CDUS could be done in two conditions, flaccid state and full erect state, with CDUS in fully erect state being the gold standard. The procedure requires the use of intracavernous injection of vasoactive agents to stimulate the erect

state (Pharmacopenile Doppler Ultrasonography) [19,44–47]. On the contrary, CDUS in flaccid state is done without any stimulation to the penis. Assessment in flaccid state is considered more comfortable than Pharmacopenile Doppler Ultrasonography (PPDU), because it is a non-invasive assessment. CDUS of the flaccid penis, according to studies could equally reflect penile vasculature condition as the fully erect state [34–37,48]. Parameter to be assessed in CDUS are arterial diameter, Peak Systolic Velocity (PSV), and Resistive Index (RI). But, in flaccid state, only PSV which had a significance in determining ED and for monitoring therapy.

In addition, VEGF is a protein belonging to the growth factor family and has a unique role in stimulating vascular regeneration [22,49,50]. There are five isoforms of VEGF have been known up until now, which are VEGF-A, VEGF-B, VEGF-C, VEGF-D, and Placenta Growth Factor (PGF) [51]. The receptors of VEGF-A are found on the endothelial tissue. VEGF-A is known for having the effect to stimulate the blood vessel angiogenesis process due to hypoxic condition and tissue trauma [52]. There was no previous study about VEGF parameter for evaluation of Li-ESWT therapy.

The mechanism behind ESWT is micro trauma. Low intensity shock waves which were delivered to the cavernous tissues causing micro traumas in the cavernous tissues. In regard most cavernous tissue are consisted of vasculature tissue (sinuses and vessels), the micro traumas were expected to happen in the vasculature tissues. The traumas, specifically being shear trauma, induce the release pro-inflammatory substances which lead to the release of the pro-angiogenesis substances, such as VEGF.

In the control group, there was clinical improvement and increased PSV parameters without any significant changes in VEGF levels. As stated before, PDE-5 inhibitor do indeed improve the clinical outcome of ED. That is the main cause of its being the chosen therapy for first line treatment. The increase of PSV in the control group might be caused by the vasodilatation in the penile vasculature as the main effect of the inhibition of PDE-5 enzyme. The unchanged level of VEGF showed that PDE-5 inhibitor does not have the capability to repair the endothelial dysfunction which was the underlying mechanism of this type of ED.

Meanwhile, in the experimental group, the increase in PSV and VEGF levels supported the clinical improvement, which was higher than that in the control group. The tremendous increase of PSV and VEGF in the experimental group was likely due to the Li-ESWT procedure (in regard that the PDE-5 inhibitor effect is same). Li-ESWT induced micro trauma caused by the shear process done in the tissue from the shock wave movement in the penile perivascular tissue, which then stimulating the regeneration process by attracting the pro-inflammatory substances, and pro-proliferative substances, such as VEGF, which then stimulated the generation of new blood vessel in the cavernous tissue. These results have shown that tadalafil alone

could not achieve significant increase in VEGF level (in control group), while the addition of Li-ESWT procedure to the tadalafil therapy produced better results. Li-ESWT was proven to be more superior to tadalafil therapy in this case, or maybe this effect happened due to the synergism of both tadalafil and Li-ESWT therapies. Nevertheless, it is clear that PDE-5 inhibitor only focused on vasodilatory effect, whilst Li-ESWT had done more by repairing the underlying mechanism. But, of course, the effect of Li-ESWT is not instantaneous, that is why Li-ESWT is better if used as a combination with other means of therapy [53].

Previous studies have similar results in terms of clinical improvement and sexual satisfaction [13,14,54–56]. Meanwhile, a previous study used PSV parameters in a relaxed state to evaluate the efficacy of Li-ESWT, and the results were similar to our study [48]. As for the assessment of VEGF levels, no human studies have been published before. This study was the first study to improve the erectile dysfunction that using Li-ESWT by examining the VEGF and PSV parameters.

5. Conclusions

This trial proved that the combination therapy of 2.5 mg oral daily tadalafil and twice weekly Li-ESWT were superior to 2.5 mg oral daily tadalafil alone in improving IIEF-5 score, EHS score, PSV parameters, and plasma level VEGF in mild, mild-moderate, and moderate erectile dysfunction patients. In conclusion, the combination therapy of Li-ESWT and tadalafil improved erectile dysfunction, specifically based on PSV and VEGF parameters.

Author contributions

AS, AJ, RNF, and TDT designed the research study. AJ, AS, and RNF performed the research. MF provided help and advice on clinical laboratory results. MHSA provided help and advice on radiological results. BU provided help and advice on statistical method. AJ, AS, RNF, AA, MPBDP, TDT analyzed the data. AS, AJ, SWL wrote the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

This study was approved by Ethical Board for Health Research, Universitas Airlangga and Dr. Soetomo Hospital with ethical certificate number 1690/KEPK/XII/2019. Written informed consents were obtained from all participants prior to the study. This study was also registered in [ClinicalTrials.gov](https://www.clinicaltrials.gov) with Registration ID: NCT05043896.

Acknowledgment

Gratitude is expressed to Department of Medical Biology, Faculty of Medicine Universitas Airlangga and Dr. Soetomo General Academic Hospital in Surabaya which provided support for this study.

Funding

This research received no external funding.

Conflict of interest

The authors declare no conflict of interest.

References

- [1] Burnett AL, Nehra A, Breau RH, Culkin DJ, Faraday MM, Hakim LS, *et al.* Erectile Dysfunction: AUA Guideline. *Journal of Urology*. 2018; 200: 633–641.
- [2] Sanchez E, Pastuszak AW, Khera M. Erectile dysfunction, metabolic syndrome, and cardiovascular risks: facts and controversies. *Translational Andrology and Urology*. 2017; 6: 28–36.
- [3] Teloken PE, Mulhall JP. Impact of phosphodiesterase type 5 inhibitors on endothelial function. *Reviews in Urology*. 2008; 10: 26–30.
- [4] Persu C, Cauni V, Gutue S, Albu ES, Jinga V, Geavlete P. Diagnosis and treatment of erectile dysfunction—a practical up-date. *Journal of Medicine and Life*. 2009; 2: 394–400.
- [5] Kaya C, Uslu Z, Karaman I. Is endothelial function impaired in erectile dysfunction patients? *International Journal of Impotence Research*. 2006; 18: 55–60.
- [6] Aversa A, Bruzziches R, Francomano D, Natali M, Gareri P, Spera G. Endothelial dysfunction and erectile dysfunction in the aging man. *International Journal of Urology*. 2010; 17: 38–47.
- [7] Moon KH, Park SY, Kim YW. Obesity and Erectile Dysfunction: from Bench to Clinical Implication. *The World Journal of Men's Health*. 2019; 37: 138.
- [8] Chu NV, Edelman SV. Erectile dysfunction and diabetes. *Current Diabetes Reports*. 2002; 2: 60–66.
- [9] Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D, Montorsi F, *et al.* Guidelines on Male Sexual Dysfunction: Erectile Dysfunction and Premature Ejaculation. *European Urology*. 2010; 57: 804–814.
- [10] Mobley DF, Khera M, Baum N. Recent advances in the treatment of erectile dysfunction. *Postgraduate Medical Journal*. 2017; 93: 679–685.
- [11] Pan MM, Raees A, Kovac JR. Low-Intensity Extracorporeal Shock Wave as a Novel Treatment for Erectile Dysfunction. *American Journal of Men's Health*. 2016; 10: 146–148.
- [12] Kałka D, Gebala J, Smoliński R, Rusiecki L, Pilecki W, Zdrojowy R. Low-energy Shock Wave Therapy—a Novel Treatment Option for Erectile Dysfunction in Men with Cardiovascular Disease. *Urology*. 2017; 109: 19–26.
- [13] Man L, Li G. Low-intensity Extracorporeal Shock Wave Therapy for Erectile Dysfunction: a Systematic Review and Meta-analysis. *Urology*. 2018; 119: 97–103.
- [14] Lu Z, Lin G, Reed-Maldonado A, Wang C, Lee YC, Lue TF. Low-intensity Extracorporeal Shock Wave Treatment Improves Erectile Function: a Systematic Review and Meta-analysis. *European Urology*. 2017; 71: 223–233.
- [15] Hatzichristou D. Low-Intensity Extracorporeal Shock Waves Therapy (LI-ESWT) for the treatment of erectile dysfunction: where do we stand? *European Urology*. 2017; 71: 234–236.
- [16] Lei H, Liu J, Li H, Wang L, Xu Y, Tian W, *et al.* Low-Intensity Shock Wave Therapy and its Application to Erectile Dysfunction. *The World Journal of Men's Health*. 2013; 31: 208.
- [17] Rizk PJ, Krieger JR, Kohn TP, Pastuszak AW. Low-Intensity Shockwave Therapy for Erectile Dysfunction. *Sexual Medicine Reviews*. 2018; 6: 624–630.
- [18] Gruenwald I, Appel B, Vardi Y. Low-Intensity Extracorporeal Shock Wave Therapy—a Novel Effective Treatment for Erectile Dysfunction in Severe ED Patients Who Respond Poorly to

- PDE5 Inhibitor Therapy. *The Journal of Sexual Medicine*. 2012; 9: 259–264.
- [19] Yamaçake KGR, Carneiro F, Cury J, Lourenço R, Françolin PC, Piovesan AC, *et al.* Low-intensity shockwave therapy for erectile dysfunction in kidney transplant recipients. a prospective, randomized, double blinded, sham-controlled study with evaluation by penile Doppler ultrasonography. *International Journal of Impotence Research*. 2019; 31: 195–203.
- [20] Porst H. Review of the Current Status of Low Intensity Extracorporeal Shockwave Therapy (Li-ESWT) in Erectile Dysfunction (ED), Peyronie's Disease (PD), and Sexual Rehabilitation after Radical Prostatectomy with Special Focus on Technical Aspects of the Different Marketed ESWT Devices Including Personal Experiences in 350 Patients. *Sexual Medicine Reviews*. 2021; 9: 93–122.
- [21] Sokolakis I, Hatzichristodoulou G. Clinical studies on low intensity extracorporeal shockwave therapy for erectile dysfunction: a systematic review and meta-analysis of randomised controlled trials. *International Journal of Impotence Research*. 2019; 31: 177–194.
- [22] Campbell JD, Milenkovic U, Usta MF, Albersen M, Bivalacqua TJ. The good, bad, and the ugly of regenerative therapies for erectile dysfunction. *Translational Andrology and Urology*. 2020; 9: S252–S261.
- [23] Brunkhorst O, Wells L, Teeling F, Muir G, Muneer A, Ahmed K. A systematic review of the long-term efficacy of low-intensity shockwave therapy for vasculogenic erectile dysfunction. *International Urology and Nephrology*. 2019; 51: 773–781.
- [24] Liu MC, Chang ML, Wang YC, Chen WH, Wu CC, Yeh SD. Revisiting the Regenerative Therapeutic Advances Towards Erectile Dysfunction. *Cells*. 2020; 9: 1250.
- [25] Chung E, Lee J, Liu CC, Taniguchi H, Zhou HL, Park HJ. Clinical Practice Guideline Recommendation on the Use of Low Intensity Extracorporeal Shock Wave Therapy and Low Intensity Pulsed Ultrasound Shock Wave Therapy to Treat Erectile Dysfunction: the Asia-Pacific Society for Sexual Medicine Position Statement. *The World Journal of Men's Health*. 2021; 39: 1–8.
- [26] Rompe JD, Kirkpatrick CJ, Küllmer K, Schwitalle M, Krischek O. Dose-related effects of shock waves on rabbit tendo Achillis. *The Journal of Bone and Joint Surgery*. 1998; 80: 546–552.
- [27] Ortac M, Kucukergin C, Salabas E, Seekin S, Kadioglu A. Effect of low-energy shockwave therapy on angiogenic factors in the penile tissue of diabetic rats. *Turkish Journal of Urology*. 2017; 43: 130–134.
- [28] Nishida T, Shimokawa H, Oi K, Tatewaki H, Uwatoku T, Abe K, *et al.* Extracorporeal Cardiac Shock Wave Therapy Markedly Ameliorates Ischemia-Induced Myocardial Dysfunction in Pigs in Vivo. *Circulation*. 2004; 110: 3055–3061.
- [29] Wang CJ, Wang FS, Yang KD, Weng LH, Hsu CC, Huang CS, *et al.* Shock wave therapy induces neovascularization at the tendon–bone junction. a study in rabbits. *Journal of Orthopaedic Research*. 2003; 21: 984–989.
- [30] Hansen LK, Schröder HD, Lund L, Rajagopal K, Maduri V, Sellathurai J. The effect of low intensity shockwave treatment (Li-SWT) on human myoblasts and mouse skeletal muscle. *BMC Musculoskeletal Disorders*. 2017; 18: 557.
- [31] Wang CJ, Huang HY, Pai CH. Shock wave-enhanced neovascularization at the tendon–bone junction: an experiment in dogs. *The Journal of Foot and Ankle Surgery*. 2002; 41: 16–22.
- [32] Fode M, Hatzichristodoulou G, Serefoglu EC, Verze P, Albersen M. Low-intensity shockwave therapy for erectile dysfunction: is the evidence strong enough? *Nature Reviews Urology*. 2017; 14: 593–606.
- [33] Yahata K, Kanno H, Ozawa H, Yamaya S, Tateda S, Ito K, *et al.* Low-energy extracorporeal shock wave therapy for promotion of vascular endothelial growth factor expression and angiogenesis and improvement of locomotor and sensory functions after spinal cord injury. *Journal of Neurosurgery*. 2016; 25: 745–755.
- [34] Chen LD, Pan FS, Zhou LY, Liu YB, Lv JY, Xu M, *et al.* Value of flaccid penile ultrasound in screening for arteriogenic impotence: a preliminary prospective study. *BMC Medical Imaging*. 2018; 18: 40.
- [35] Vipul A. Color Doppler sonography of the flaccid penis: role in evaluation of erectile dysfunction. *European Congress of Radiology*. 2018. Available at: <http://epos.mysr.org/poster/ecr2018/C-0822> (Accessed: 27 November 2019).
- [36] Kahvecioğlu N, Kurt A, İpek A, Yazicioğlu K, Akbulut Z. Predictive value of cavernosal peak systolic velocity in the flaccid penis. *Advances in Medical Sciences*. 2009; 54: 233–238.
- [37] Sen J, Singh R, Airon RK, Godara R. Colour Doppler Sonography of Flaccid Penis in Evaluation of Erectile Dysfunction. *Asian Journal of Surgery*. 2007; 30: 122–125.
- [38] Kanda Y. Investigation of the freely available easy-to-use software 'EZ' for medical statistics. *Bone Marrow Transplantation*. 2013; 48: 452–458.
- [39] Hatzimouratidis K, Giuliano F, Moncada I. EAU guidelines on erectile dysfunction, premature ejaculation, penile curvature and priapism (European Association of Urology, Arnhem, The Netherlands, 2018). 2018. Available at: <https://uroweb.org/wp-content/uploads/EAU-Guidelines-on-Male-Sexual-Dysfunction-2018-large-text.pdf> (Accessed: 8 February 2020).
- [40] LeRoy TJ, Broderick GA. Doppler Blood Flow Analysis of Erectile Function: who, when, and how. *Urologic Clinics of North America*. 2011; 38: 147–154.
- [41] Golijanin D, Singer E, Davis R, Bhatt S, Seftel A, Dogra V. Doppler evaluation of erectile dysfunction – Part 2. *International Journal of Impotence Research*. 2007; 19: 43–48.
- [42] Tung SY, Chang YK, Liu SP, Hsieh JT, Chang HC. Correlation between penile Doppler ultrasound findings and penile arterial insufficiency under percutaneous transluminal angioplasty for patients with erectile dysfunction. *European Urology Supplements*. 2018; 17: e1579.
- [43] Tung SY, Chang YK, Chang HC, Wang TD, Wen-Jeng L, Liu SP, *et al.* Current cut-off value for peak systolic velocity and resistance index under penile doppler ultrasound not adequate enough for patient with erectile dysfunction. *Journal of Urology*. 2019; 201: e759–e760.
- [44] Mutnuru PC, Ramanjaneyulu HK, Susarla R, Yarlagadda J, Devraj R, Palanisamy P. Pharmacologic Penile Duplex Ultrasonography in the Evaluation of Erectile Dysfunction. *Journal of Clinical and Diagnostic Research*. 2017; 11: TC07–TC10.
- [45] Jung DC, Park SY, Lee JY. Penile Doppler ultrasonography revisited. *Ultrasonography*. 2018; 37: 16–24.
- [46] Berookhim BM. Doppler Duplex Ultrasonography of the Penis. *The Journal of Sexual Medicine*. 2016; 13: 726–731.
- [47] Sikka SC, Hellstrom WJG, Brock G, Morales AM. Standardization of Vascular Assessment of Erectile Dysfunction. *The Journal of Sexual Medicine*. 2013; 10: 120–129.
- [48] Gatkin M, Sopotov A. 557 Doppler test in penis flaccid state to assess erectile dysfunction severity and shockwave treatment outcomes. *The Journal of Sexual Medicine*. 2018; 15: S331–S332.
- [49] Ferrara N. Vascular Endothelial Growth Factor: Basic Science and Clinical Progress. *Endocrine Reviews*. 2004; 25: 581–611.
- [50] Sahara M, Sata M, Morita T, Nakajima T, Hirata Y, Nagai R. A Phosphodiesterase-5 Inhibitor Vardenafil Enhances Angiogenesis through a Protein Kinase G–Dependent Hypoxia-Inducible Factor-1/Vascular Endothelial Growth Factor Pathway. *Arterio-sclerosis, Thrombosis, and Vascular Biology*. 2010; 30: 1315–1324.
- [51] Cêbe Suarez S, Pieren M, Cariolato L, Am S, Hoffmann U,

- Bogucki A, *et al.* A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. *Cellular and Molecular Life Sciences*. 2006; 63: 2067–2077.
- [52] Mecollari V, Nieuwenhuis B, Verhaagen J. A perspective on the role of class III semaphorin signaling in central nervous system trauma. *Frontiers in Cellular Neuroscience*. 2014; 8: 328.
- [53] Capece M, Verze P, Creta M, La Rocca R, Persico F, Spirito L, *et al.* Efficacy and safety of low-intensity shock-wave therapy plus tadalafil 5 mg once daily in men with type 2 diabetes mellitus and erectile dysfunction: a matched-pair comparison study. *Asian Journal of Andrology*. 2020; 22: 379.
- [54] Vardi Y, Appel B, Jacob G, Massarwi O, Gruenwald I. Can Low-Intensity Extracorporeal Shockwave Therapy Improve Erectile Function? A 6-Month Follow-up Pilot Study in Patients with Organic Erectile Dysfunction. *European Urology*. 2010; 58: 243–248.
- [55] Srinivasan VS, Reddy RK, Shultz T, Denes B. Low intensity extracorporeal shockwave therapy for erectile dysfunction: a study in an Indian population. *The Canadian Journal of Urology*. 2015; 22: 7614–7622.
- [56] Clavijo RI, Kohn TP, Kohn JR, Ramasamy R. Effects of Low-Intensity Extracorporeal Shockwave Therapy on Erectile Dysfunction: A Systematic Review and Meta-Analysis. *The Journal of Sexual Medicine*. 2017; 14: 27–35.